CEO.CA's Inside the Boardroom: Ventripoint Diagnostics: We Made Ultrasound as Good as MRI - Now Here's How We Scale It

Rhea-AI Summary

Ventripoint Diagnostics (TSXV: VPT / OTC Pink: VPTDF) featured in CEO.CA's "Inside the Boardroom" interview on November 27, 2025, with CEO Hugh MacNaught and Congenital Heart Defect Program Director Joe Hostetter.

The segment highlights Ventripoint's claim of making point-of-care ultrasound comparable to MRI and discusses commercialization and scaling strategy. Viewers are directed to CEO.CA and a YouTube video for the full interview and to join investor discussions at the provided community link.

Key Figures

Founding year: 2012

1 metrics

Founding year 2012 Year CEO.CA was founded

Market Reality Check

Price: $0.0882 Vol: Volume 60,753 is close to...

normal vol

$0.0882 Last Close

Volume Volume 60,753 is close to the 20-day average of 59,243 (near-normal activity). normal

Technical Shares at 0.0746 are trading below the 200-day MA of 0.09 and 44.82% under the 52-week high.

Peers on Argus

Peers show mixed moves: AURORA SPINE (ASAPF) up 0.99%, PHARMCHEM (PCHM) up 0.27%...

Peers show mixed moves: AURORA SPINE (ASAPF) up 0.99%, PHARMCHEM (PCHM) up 0.27%, PERIMETER MED IMAGING AI (PYNKF) down 1.04%, BIOTRICITY (BTCY) down 8.94%, while VPTDF is down 2.2%, pointing to stock-specific trading rather than a broad sector move.

Historical Context

1 past event · Latest: Aug 13 (Positive)

Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Aug 13	Regulatory/commercial update	Positive	-1.6%	FDA approval and pivot to subscription model with lower-cost cardiac imaging.

Pattern Detected

The prior clearly positive FDA approval and commercialization update was followed by a modest negative price reaction, suggesting a tendency toward weak or contrary responses to good news.

Recent Company History

On Aug 13, 2025, Ventripoint Diagnostics highlighted FDA approval for its heart ultrasound software, which turns standard ultrasound machines into tools that can rival MRI at much lower cost. The company outlined a pivot to a subscription-based model, noting heart scans at 5.5 times lower cost and equipment at less than 10% of conventional MRI systems, with revenue generation expected before year-end. That news saw a -1.59% 24-hour reaction. Today’s boardroom interview extends visibility on the business rather than introducing new financial or regulatory milestones.

Market Pulse Summary

This announcement highlights an executive interview featuring Ventripoint Diagnostics’ leadership, e...

Analysis

This announcement highlights an executive interview featuring Ventripoint Diagnostics’ leadership, extending visibility following the FDA approval and commercialization plans outlined on Aug 13, 2025. It reinforces the company’s positioning in advanced cardiac imaging but does not add new regulatory or financial milestones. Investors may watch for concrete updates on subscription uptake, revenue generation referenced in earlier communications, and any further clinical or market adoption data that clarify the commercial trajectory.

Key Terms

ultrasound, mri, congenital heart defect, otc pink

4 terms

ultrasound medical

"We Made Ultrasound as Good as MRI - Now Here's How We Scale It"

Ultrasound uses high-frequency sound waves—like sonar or a bat’s echo—to create images or deliver targeted therapy inside the body without cutting skin. Investors care because ultrasound devices and related services drive sales across hospitals, clinics and outpatient centers, often involve recurring consumables and software upgrades, and are sensitive to technology advances, regulatory approval and reimbursement policies that affect a supplier’s revenue and growth.

mri medical

"We Made Ultrasound as Good as MRI - Now Here's How We Scale It"

Magnetic resonance imaging (MRI) is a medical scan that uses magnetic fields and radio waves to create detailed pictures of the inside of the body, like a high-resolution camera for tissues and organs. Investors care because MRI drives demand for imaging machines, hospital services, diagnostics and can be central to clinical trial results and regulatory decisions—changes in MRI use or technology can affect revenue, capital spending and reimbursement in healthcare and medical device markets.

congenital heart defect medical

"and Joe Hostetter, Congenital Heart Defect Program Director."

A congenital heart defect is a structural problem with the heart or its major vessels that is present at birth, ranging from small holes to missing or misshapen valves or chambers. Investors track these conditions because they drive demand for surgeries, medical devices, drugs, lifelong care and screening, and can affect regulatory approvals, reimbursement and long-term cost forecasts—think of it like a building with a flawed plumbing layout that requires specific repairs and ongoing maintenance.

otc pink financial

"Ventripoint Diagnostics Ltd. (TSXV: VPT) (OTC Pink: VPTDF)"

OTC Pink is a trading tier for stocks that are not listed on major exchanges and generally have the least regulatory oversight and public disclosure. Think of it as a flea market for shares: prices can swing wildly and it can be hard to find reliable information or buyers, so investors face higher risks of loss, limited liquidity, and greater chance of fraud or sudden price jumps.

AI-generated analysis. Not financial advice.

Toronto, Ontario--(Newsfile Corp. - November 27, 2025) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining explorers.

Founded in 2012, CEO.CA, a wholly owned subsidiary of EarthLabs, Inc., is one of the most popular free financial websites and apps in Canada and for investors globally - with industry leading audience engagement and mobile functionality. Millions of people visit CEO.CA each year to connect with investors from around the world, share knowledge and view impactful stories about stocks, commodities, and emerging companies.

Meet the Executives Shaping the Biotechnology Landscape

'Inside the Boardroom' is more than just an interview series - it's a chance to gain firsthand knowledge from industry leaders, understanding their vision, challenges, and strategy.

We caught up with Hugh MacNaught, CEO of Ventripoint Diagnostics Ltd. (TSXV: VPT) (OTC Pink: VPTDF), and Joe Hostetter, Congenital Heart Defect Program Director. Follow what investors are saying and join our community: https://ceo.ca/vpt

Ventripoint Diagnostics

(TSXV: VPT) (OTC Pink: VPTDF)

Cannot view this video? Visit:
https://www.youtube.com/watch?v=muLuVfEAX6w

Tune in to 'Inside the Boardroom' each week and be part of the conversation that's shaping the business landscape. Visit CEO.CA or our YouTube page for hundreds more executive interviews from CEO.CA here.

Interested in showcasing your company on 'Inside the Boardroom'? Get in touch with our team at sales@ceo.ca for further details and opportunities.

About CEO.CA

The leading community for investors & traders in junior resource & venture stocks. CEO.CA is one of the most popular free financial websites and apps in Canada and for small-cap investors globally -- with industry leading audience engagement and mobile functionality. Since 2012, CEO.CA has brought millions of investors together from over 164 countries to discuss their portfolio holdings and find new investment opportunities. Download our App on iOS or Android marketplace or visit us today at CEO.CA to set up your free account.

CEO.CA is a wholly owned subsidiary of EarthLabs, Inc.

For further information please contact:

CEO.CA
Email: hello@ceo.ca
Website: CEO.CA

Neither the TSX Venture Exchange ("TSXV"), OTC Best Market "(OTCQX") nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement

The information regarding any issuer contained or referred to in any interviews conducted by CEO.CA has been furnished by such issuer directly, and neither CEO.CA nor any of its affiliates or principals assumes any responsibility for the accuracy or completeness of such information or for any failure by an issuer to ensure disclosure of events or facts which may affect the significance or accuracy of any such information.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This news release contains forward-looking information which involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release may include, but is not limited to, the objectives, goals, future plans, statements regarding exploration results and exploration and/or development plans of companies featured on the CEO.CA platform. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, capital and operating costs varying significantly from estimates, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, fluctuations in commodity prices, delays in the development of projects, currency risk and the other risks involved in the applicable exploration and development industry, and those risks set out in the public documents of such companies filed on SEDAR or elsewhere from time to time. Undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. CEO.CA disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276121

FAQ

When was Ventripoint Diagnostics interviewed on CEO.CA 'Inside the Boardroom' (VPTDF)?

The interview with Ventripoint aired on November 27, 2025.

Who spoke for Ventripoint Diagnostics in the CEO.CA interview (TSXV: VPT)?

Speakers were Hugh MacNaught, CEO, and Joe Hostetter, Congenital Heart Defect Program Director.

Where can investors watch the Ventripoint Diagnostics CEO.CA interview for VPTDF?

The interview is available on CEO.CA and on YouTube at https://www.youtube.com/watch?v=muLuVfEAX6w.

What key claim about Ventripoint's technology was discussed in the VPT interview?

The interview discusses Ventripoint's claim of making ultrasound as good as MRI and scaling that capability.

How can companies apply to appear on CEO.CA 'Inside the Boardroom' (investor outreach)?

Companies can contact CEO.CA sales at sales@ceo.ca to inquire about showcasing on the series.